Peptide Comparison
PT-141 vs Melanotan II
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Melanotan II combined with novel peptides during dose-finding: High risk per peptide research literature. Masks individual peptide response (pigmentation, nausea, BP overlap); MC1R activation raises melanoma/mole darkening concerns when dose-finding other compounds.
Data-derived verdict
PT-141 has stronger documented evidence (FDA-Approved) than Melanotan II (Anecdotal (Editor-Flagged Unsafe)) while both occupy the mc4r / melanocortin classes. When clinical-evidence tier is the deciding factor, PT-141 is the safer pick. Melanotan II may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: nausea. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| PT-141 | Melanotan II | |
|---|---|---|
| Class | Melanocortin receptor agonist (FDA-approved) | Melanocortin receptor agonist (nonselective) |
| Drug class | Sexual-Health | Dermatologic |
| Mechanism | MC4R agonist in CNS; induces sexual desire independent of vascular mechanisms | Nonselective agonist at MC1R/MC3R/MC4R/MC5R; stimulates melanogenesis and sexual arousal pathways |
| Route | SC / Intranasal | SC injection |
| Half-life | ~2 hrs | ~1-3 hrs |
| Dosage (research) | 1.75 mg SC 45 min before sex (FDA label) | 0.25-1 mg SC daily titrating up |
| Evidence tier | FDA-Approved | Anecdotal (Editor-Flagged Unsafe) |
| Research depth | 146 indexed | 197 indexed |
| Availability | Prescription | Research Chemical |
| Reported risks | Nausea (~40%); flushing; headache; transient BP increase; focal hyperpigmentation | Nausea; facial flushing; melanoma/mole darkening concerns; priapism; BP effects; rhabdomyolysis reports |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick PT-141 or Melanotan II?
PT-141 has stronger documented evidence (FDA-Approved) than Melanotan II (Anecdotal (Editor-Flagged Unsafe)) while both occupy the mc4r / melanocortin classes. When clinical-evidence tier is the deciding factor, PT-141 is the safer pick. Melanotan II may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between PT-141 and Melanotan II?
PT-141 is classed as Melanocortin receptor agonist (FDA-approved); Melanotan II is classed as Melanocortin receptor agonist (nonselective). Reported mechanism: PT-141, MC4R agonist in CNS; induces sexual desire independent of vascular mechanisms; Melanotan II, Nonselective agonist at MC1R/MC3R/MC4R/MC5R; stimulates melanogenesis and sexual arousal pathways. Reported half-life: PT-141, ~2 hrs; Melanotan II, ~1-3 hrs. Routes in published studies: PT-141, SC / Intranasal; Melanotan II, SC injection.
Which has stronger evidence, PT-141 or Melanotan II?
PT-141 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. PT-141 is graded FDA-Approved, with 6 cited sources on its reference page and 146 indexed studies. Melanotan II is graded Anecdotal (Editor-Flagged Unsafe), with 3 cited sources on its reference page and 197 indexed studies.
Which is more accessible, PT-141 or Melanotan II?
PT-141 is FDA-approved and Melanotan II is not. Catalog status: PT-141, Prescription; Melanotan II, Research Chemical. Melanotan II's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are PT-141 and Melanotan II ever combined?
PT-141 and Melanotan II appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…